Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 19/20 | 0.47 |
| ▸ | JAK2 | O60674 | 16/20 | 0.47 |
| ▸ | JAK3 | P52333 | 6/20 | 0.47 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13142264 | 0.77 | JAK2 (0.59) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL10099400 | 0.77 | JAK2 (0.52) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL10099384 | 0.77 | JAK2 (0.56) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL565541 | 0.77 | JAK2 (0.56) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL10090071 | 0.77 | JAK1 (0.44) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL565497 | 0.75 | JAK2 (0.56) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL10099358 | 0.74 | JAK1 (0.65) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL10090085 | 0.74 | JAK1 (0.58) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL10090084 | 0.74 | JAK1 (0.58) | JAK1JAK2JAK3TYK2AURKA | |
| SCHEMBL10090063 | 0.74 | JAK1 (0.52) | JAK1JAK2JAK3TYK2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| WO-2010119875-A1 | FUSED PYRROLOPYRIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.